GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » EV-to-EBITDA

iSpecimen (iSpecimen) EV-to-EBITDA : 0.25 (As of May. 01, 2024)


View and export this data going back to 2021. Start your Free Trial

What is iSpecimen EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, iSpecimen's enterprise value is $-2.17 Mil. iSpecimen's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.75 Mil. Therefore, iSpecimen's EV-to-EBITDA for today is 0.25.

The historical rank and industry rank for iSpecimen's EV-to-EBITDA or its related term are showing as below:

ISPC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.43   Med: 0   Max: 0.6
Current: 0.25

During the past 6 years, the highest EV-to-EBITDA of iSpecimen was 0.60. The lowest was -23.43. And the median was 0.00.

ISPC's EV-to-EBITDA is ranked better than
94.12% of 119 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.29 vs ISPC: 0.25

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), iSpecimen's stock price is $0.292. iSpecimen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.230. Therefore, iSpecimen's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


iSpecimen EV-to-EBITDA Historical Data

The historical data trend for iSpecimen's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen EV-to-EBITDA Chart

iSpecimen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - -7.50 0.32 0.03

iSpecimen Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 -0.14 -0.52 -0.02 0.03

Competitive Comparison of iSpecimen's EV-to-EBITDA

For the Diagnostics & Research subindustry, iSpecimen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iSpecimen's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where iSpecimen's EV-to-EBITDA falls into.



iSpecimen EV-to-EBITDA Calculation

iSpecimen's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-2.170/-8.753
=0.25

iSpecimen's current Enterprise Value is $-2.17 Mil.
iSpecimen's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iSpecimen  (NAS:ISPC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

iSpecimen's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.292/-1.230
=At Loss

iSpecimen's share price for today is $0.292.
iSpecimen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.230.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


iSpecimen EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of iSpecimen's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


iSpecimen (iSpecimen) Business Description

Traded in Other Exchanges
N/A
Address
450 Bedford Street, Lexington, MA, USA, 02420
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Executives
Benjamin Bielak officer: Chief Information Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley officer: Chief Financial Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile director 450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross director, 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d. director C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence director 450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl director 450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli director, officer: CEO, President 450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan director, officer: COO, Secretary, Treasurer 450 BEDFORD STREET, LEXINGTON MA 02420